Kyntra Bio (NASDAQ:KYNB) Upgraded at HC Wainwright

HC Wainwright upgraded shares of Kyntra Bio (NASDAQ:KYNB) to a strong-buy rating in a research report released on Friday,Zacks.com reports.

KYNB has been the topic of a number of other research reports. Zacks Research cut shares of Kyntra Bio from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 6th. Weiss Ratings began coverage on shares of Kyntra Bio in a research report on Wednesday, January 14th. They set a “sell (d+)” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Kyntra Bio presently has a consensus rating of “Hold”.

Kyntra Bio Price Performance

KYNB stock opened at $6.93 on Friday. The company has a market capitalization of $28.07 million, a price-to-earnings ratio of 0.13 and a beta of 0.84. Kyntra Bio has a one year low of $4.85 and a one year high of $12.60.

Kyntra Bio Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.